Trials / Withdrawn
WithdrawnNCT00892892
Sympathetic Nerve Activity in Renal Failure
Role of the Sympathetic Nerve System for the Pathogenesis and Progression of Chronic Kidney Failure
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Erlangen-Nürnberg Medical School · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose is to assess the role of sympathetic activation for the development and progression of chronic renal failure. Using microneurography sympathetic activity will be registered in various stages of kidney affection or failure and hypertension. A sympatholytic agent will be compared with a non-sympatholytic drug to asses the effect sympathetic activation and on the progression of kidney disease. The effects of a sympatholytic agent on cardiovascular reactivity to various stressors wil be examined.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rilmenidine | 1 mg Rilmenidine per day versus |
| DRUG | Nitrendipine | 20 mg Nitrendipine per day |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2009-05-05
- Last updated
- 2015-03-17
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00892892. Inclusion in this directory is not an endorsement.